Interactive role of breast cancer on dyslipidemia and hypertension metabolic risk according to treatment exposure and menopausal status

Abstract

Abstract Background Breast cancer (BC) is the principal cause of cancer related deaths among women worldwide. The available evidence suggests that cardio-metabolic risk factors such as dyslipidemia and hypertension may contribute differently to breast cancer severity and pathogenesis. The aim of this study is to evaluate the interactive role of BC on dyslipidemia and HTN risk according to the type of treatment exposure and menopausal status. Method Observational experimental design implemented; permit to include 134 newly-diagnosed patients who were naïve to any type of treatment interventions and 262 recently-diagnosed patients during their first three months of treatments’ exposure including chemotherapy treatments. Patients with breast cancer were evaluated for dyslipidemia and hypertension biomarkers. Results About 5.0% of breast cancer patients had dyslipidemia. The prevalence of increased triglycerides and total cholesterol were more frequent (p < 0.05) in recently-diagnosed group than in newly-diagnosed patients. While 23% of patients had overt hypertension, with higher (p < 0.05) prevalence in chemo group (28%), triglycerides was higher (p < 0.05) in postmenopausal than premenopausal BC patients (221.0 ± 5.9 vs. 195 ± 4.7 mg/dl). Similarly, the prevalence of abnormal systolic blood pressure (9% vs. 5%) and diastolic blood pressure (11% vs. 7%) was higher (p < 0.05) in postmenopausal patients. Conclusion Dyslipidemia and hypertension biomarkers were prevalent among breast cancer patients and the risk increased in postmenopausal women and after treatments’ exposure specially chemotherapy. This conclusion requires a closer attention by healthcare professionals in order to improve the outcomes after diagnosis and to enhance treatment exposure regarding postmenopausal women.